Clinical trial · Observational
Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma
Efficacy of Chemotherapy or Chemo-anti-PD-1 Combination After Failed Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: a Series From Lysa Centers.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known. In this context, the optimal treatment for patients who failed after anti-PD-1 therapy is an issue. To better assess their outcome, the investigators retrospectively analyzed the characteristics and outcome of patients from 14 LYSA (The Lymphoma Study Association) centers who lost response to anti-PD-1 therapy and received additional CT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evaluate the improvement in response from the end of anti-PD-1 monotherapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group 1 Sequential strategy
- description
- Patients for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (19 patients, 63%).
- interventionNames
- Biological: Evaluate the improvement in response from the end of anti-PD-1 monotherapy
- label
- Group 2 Concomitant strategy
- description
- Patients for whom a combination of CT with anti-PD-1 therapy was initiated (11 patients, 37 %).
- interventionNames
- Biological: Evaluate the improvement in response from the end of anti-PD-1 monotherapy
Primary outcomes (1)
- measure
- Overall response rate after re-exposure to chemotherapy
- timeFrame
- 10 weeks
- description
- Patient evaluation was timed by treating physicians according to the policy of each center, and all patients were evaluated after a median of 10 weeks (min 7 weeks, max 12 weeks) with PET/CT using Lugano criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Initial diagnosis of classical HL * Optional histopathology confirmation of relapse/refractory HL, (2) age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 to 2 * Patients must be have received: at least 2 prior regimens and have received or be ineligible for autologous stem cell transplant and must have received prior BV, and at least 2 cycles of single agent anti-PD-1 as last treatment before entering the study, * Patients must have inadequate response to anti-PD-1 monotherapy (progressive disease or partial response according to Lugano criteria) with at least one hypermetabolic lesion over the liver and mediastinum background at time of inclusion in the study * Previous allogeneic stem cell transplant was allowed. Patients treated with radiotherapy alone after anti-PD1 or combined with anti-PD1 treatment were not included in the study. Exclusion Criteria: \- radiotherapy in the treatment after anti-PD1
References
Publications (0)
Data not yet available